Loading organizations...

§ Private Profile · 490 Arsenal Way, Suite 100B, Watertown, Massachusetts 02472, US
Twentyeight-Seven Therapeutics is a technology company.
Twentyeight-Seven Therapeutics develops small-molecule drugs to modulate microRNA, specifically to enhance anticancer microRNA expression for therapeutic use. The company leverages deep RNA biology understanding to identify and target regulatory mechanisms. Their approach precisely influences microRNA activity, offering a novel modality for challenging diseases.
The company was founded in 2016 by Harvard Medical School professors Frank Slack, George Daley, Piotr Sliz, and Richard Gregory. Their collective expertise in biological chemistry and RNA biology informed the foundational insight into microRNA's therapeutic potential. This understanding of its critical role in oncological pathways drove the company's creation to translate discoveries into clinical solutions.
Twentyeight-Seven Therapeutics targets patients with serious medical conditions, initially focusing on oncology. The company’s vision is to discover innovative therapies by pioneering new frontiers in RNA biology. They aim to establish significant new treatment paradigms, aspiring to expand their therapeutic reach beyond current cancer applications.
Twentyeight-Seven Therapeutics has raised $80.0M across 2 funding rounds.
Twentyeight-Seven Therapeutics has raised $80.0M in total across 2 funding rounds.
Twentyeight-Seven Therapeutics (28-7) is a stealth biotechnology startup developing small-molecule drugs that modulate non-coding RNA (ncRNA) functions, particularly microRNAs (miRNAs), to treat cancer and other human diseases.[1][2][3] The company targets RNA modulating proteins (RMPs) and RNA-binding proteins to control oncogene expression, suppress mRNA translation, and promote mRNA decay, addressing cancer initiation, progression, and metastasis.[2][4] It serves patients with hard-to-treat cancers by creating a novel class of therapies beyond traditional protein-targeting drugs, with early-stage operations including a pipeline in R&D and a team of 11-50 employees generating under $1M in annual revenue.[2]
Founded as a Delaware C-Corp in 2016, 28-7 emerged from academic expertise in RNA biology and has since attracted investment from Sofinnova Partners, reflecting growing momentum in RNA therapeutics.[2][3]
Twentyeight-Seven Therapeutics was established on April 7, 2016, in Delaware as a C-Corp, with its principal operations in Watertown, MA, and a registered agent in Cambridge, MA.[2] The core technology stems from four founding scientists—leading researchers in RNA biology and cancer—who developed approaches to modulate short ncRNAs like miRNAs that regulate gene expression.[2][3] This idea emerged from insights into ncRNA's role in disease, positioning 28-7 as an early pioneer in targeting these undruggable elements with small molecules.[1][2] Early traction included building a full executive team, R&D pipeline, and website, while operating in stealth mode before gaining visibility through biotech networks.[2]
Twentyeight-Seven rides the RNA therapeutics wave, accelerated by mRNA vaccine successes and advances in CRISPR/RNA editing, shifting focus from protein-centric drugs to the "dark matter" of the genome—ncRNAs regulating 98% of transcribed human DNA.[1][2][4] Timing aligns with surging demand for precision oncology, as cancers evolve resistance to immunotherapies and kinase inhibitors, making RNA modulation a timely market force amid a $100B+ oncology sector.[2] By influencing the biotech ecosystem, 28-7 contributes to Sofinnova's portfolio of disruptive biopharma startups, fostering innovation in RNA drug discovery and potentially reshaping treatment paradigms for metastatic diseases.[3]
Recently rebranded to Redona Therapeutics, 28-7 is poised for clinical advancement, likely advancing its miRNA-modulating pipeline into trials amid booming RNA biotech funding.[3] Trends like AI-driven target identification and small-molecule RNA stabilizers will propel its growth, potentially expanding beyond cancer to fibrosis or neurodegeneration. Its influence may evolve from stealth innovator to ecosystem leader, delivering first-in-class therapies that tie back to its founding mission: revolutionizing drug discovery through ncRNA control.[2][3]
Twentyeight-Seven Therapeutics has raised $80.0M across 2 funding rounds. Most recently, it raised $15.0M Series A in May 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2019 | $15M Series A | Soffinova Partners | MPM Capital, Novartis Venture Fund, Astellas Venture Management, Johnson & Johnson Innovation, Longwood Fund, Novartis, Osage University Partners, Vertex Ventures HC | Announced |
| Sep 1, 2018 | $65M Series A | MPM Capital, Michal Silverberg | Novartis Venture Fund, Soffinova Partners, Astellas Venture Management, Johnson & Johnson Innovation, Longwood Fund, Carolyn NG | Announced |
Twentyeight-Seven Therapeutics has raised $80.0M in total across 2 funding rounds.
Twentyeight-Seven Therapeutics's investors include Soffinova Partners, MPM Capital, Novartis Venture Fund, Astellas Venture Management, Johnson & Johnson Innovation, Longwood Fund, Novartis, Osage University Partners, Vertex Ventures HC, Michal Silverberg, Carolyn Ng.